Conflict of Interest: None
Intravenous Lidocaine in the Treatment of Refractory Headache: A Retrospective Case Series
Article first published online: 10 NOV 2008
© 2008 the Authors. Journal compilation © 2008 American Headache Society
Headache: The Journal of Head and Face Pain
Volume 49, Issue 2, pages 286–291, February 2009
How to Cite
Marmura, M., Rosen, N., Abbas, M. and Silberstein, S. (2009), Intravenous Lidocaine in the Treatment of Refractory Headache: A Retrospective Case Series. Headache: The Journal of Head and Face Pain, 49: 286–291. doi: 10.1111/j.1526-4610.2008.01281.x
- Issue published online: 3 FEB 2009
- Article first published online: 10 NOV 2008
- Accepted for publication August 20, 2008.
Vol. 49, Issue 5, 803, Article first published online: 27 APR 2009
- refractory headache;
- hemicrania continua;
Background.— New treatments are needed to treat chronic daily headache (CDH) and chronic cluster headache (CCH). New treatments are needed to treat this population and intravenous (IV) lidocaine is a novel treatment for CDH.
Objective.— The aim of this study was to examine the use of IV lidocaine for refractory CDH patients in an inpatient setting.
Methods.— This was an open-label, retrospective, uncontrolled study of IV lidocaine for 68 intractable headache patients in an inpatient setting. We reviewed the medical records of patients receiving IV lidocaine between February 6, 2003 and June 29, 2005.
Results.— Pretreatment headache scores averaged 7.9 on an 11-point scale and posttreatment scores averaged 3.9 representing an average change of 4. Average length of treatment was 8.5 days. Lidocaine infusion was generally well tolerated with a low incidence of adverse events leading to discontinuation of treatment.
Conclusions.— This study suggests benefit of lidocaine treatment and the need for further prospective analyses. The mechanism of lidocaine in treating headache is unknown.